trending Market Intelligence /marketintelligence/en/news-insights/trending/lcmze0ifgco2iacscmlyzw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie's Imbruvica combination accepted for US FDA priority review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AbbVie's Imbruvica combination accepted for US FDA priority review

An application for priority review of a combination therapy with AbbVie Inc.'s Imbruvica and Roche Holding AG's Gazyva to treat two types of blood cancer has been accepted by the U.S. Food and Drug Administration.

The priority review status will expedite the process for regulatory approval of the combination of Gazyva and Imbruvica, also known as obinutuzumab and ibrutinib, respectively. Approval would mark the first FDA nod for a chemotherapy-free, protein-attacking drug combination for initial treatment of chronic lymphocytic leukemia.

The combination is being studied to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. Chronic lymphocytic leukemia is a slow-progressing blood cancer that affects certain white blood cells in bone marrow and blood. The disease impacts around 115,000 patients in the U.S., with almost 20,000 new cases diagnosed every year. Small lymphocytic lymphoma is a slow-growing lymphoma biologically similar to chronic lymphocytic leukemia in which too many immature white blood cells cause lymph nodes to become larger than normal.

The FDA acceptance is based on results of a phase 3 study called Illuminate. An independent review committee determined that the Imbruvica combination was better than combining Gazyva with chemotherapy drug chlorambucil in increasing the length of time that a patient with previously untreated leukemia and lymphoma lived without the disease worsening.

Imbruvica has been granted four breakthrough therapy designations from the FDA, and is approved to treat Waldenström's macroglobulinemia, previously treated marginal zone lymphoma, and chronic graft-versus-host disease. Additionally, the U.K.'s National Institute for Health and Care Excellence has approved Imbruvica for previously treated mantle cell lymphoma.